The Role of TNT for Rectal Cancer in Nodal Management

TNT for rectal cancer has rapidly emerged as a preferred approach for managing locally advanced cases. This strategy aims to improve systemic control and enhance pathological response rates. However, clinicians often question if this intensive therapy changes the management of lateral pelvic lymph nodes (LPLN). Historically, long-course chemoradiotherapy (LCRT) was the benchmark for determining which nodes required surgical dissection. Recent evidence now clarifies whether these old rules still apply in the modern era of total neoadjuvant therapy.

A comprehensive retrospective analysis from a high-volume tertiary care center investigated 228 patients who underwent lateral pelvic lymph node dissection (LPLND). The researchers compared outcomes between those receiving TNT and those undergoing traditional LCRT. Remarkably, the study found that 25% of the total cohort had pathologically positive lateral nodes. The internal iliac region appeared as the most frequent site of involvement. This data underscores the persistent threat lateral nodes pose, even with advanced chemotherapy protocols.

Predicting Pathological Positivity in TNT for Rectal Cancer

Identifying which patients truly benefit from LPLND is crucial for minimizing surgical morbidity. The study identified specific risk factors that significantly predict pathologically positive nodes. Specifically, patients with cT4b stage disease faced a much higher risk, with an odds ratio of 2.60. Additionally, the presence of multiple enlarged LPLN stations increased the risk nearly fourfold. Notably, the type of neoadjuvant therapy—whether TNT or LCRT—did not significantly influence the rate of positive nodes. Therefore, surgeons should maintain rigorous selection criteria regardless of the treatment intensity.

Survival outcomes further support the consistency of current surgical indications. The 3-year local recurrence-free survival (LRFS) rates were comparable between the groups, reaching 90% for the TNT cohort and 85% for LCRT. These findings suggest that TNT for rectal cancer does not eliminate the need for specialized surgical intervention in high-risk patients. Consequently, the widely adopted Ogura criteria remain a reliable guide for choosing candidates for pelvic dissection today.

Key Clinical Takeaways

• TNT and LCRT result in similar rates of pathologically positive lateral lymph nodes.


• Clinical T4b stage and multiple enlarged nodal stations are major predictors of disease.


• Current size-based selection criteria for LPLND remain valid in the TNT era.


• Long-term local recurrence-free survival is not compromised by the choice of neoadjuvant therapy.

Frequently Asked Questions

Does TNT for rectal cancer reduce the need for lateral node dissection?

No, the study indicates that TNT does not significantly lower the rate of pathologically positive lateral nodes compared to traditional chemoradiotherapy. Selection for surgery should still follow established size and risk criteria.

What are the primary risk factors for positive lateral pelvic nodes?

The main risk factors include a cT4b tumor stage and the presence of enlarged nodes in multiple pelvic stations. These factors should prompt a high suspicion of malignancy regardless of the neoadjuvant response.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Nariampalli Karthyarth M et al. Is Total Neoadjuvant Therapy the Solution to the Lateral Pelvic Lymph Nodes in Rectal Cancer? Retrospective Analysis From a High-Volume Tertiary Care Center. Ann Surg Oncol. 2026 Apr 22. doi: 10.1245/s10434-026-19701-2. PMID: 42020914.

Saklani A, et al. Neoadjuvant therapy for lateral pelvic lymph nodes: choosing between long course chemoradiation or short course radiotherapy with consolidation chemotherapy. Int J Colorectal Dis. 2025. doi: 10.1007/s10151-025-03177-5.

Garcia-Aguilar J, et al. Rectal Cancer Response to Total Neoadjuvant Therapy Predicts Organ Preservation and Survival Outcomes: The OPRA Trial. JAMA Oncol. 2024. doi: 10.1001/jamaoncol.2024.0195.